Business Wire | Sep 8, 2020 08:00AM EDT

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September

Sep. 08, 2020

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 08, 2020--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that members of its management team will participate virtually in the following upcoming conferences:

H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Monday, September 14, 2020 Presentation Time: 1:00 p.m. ET

2020 Cantor Global Healthcare ConferenceDate: Tuesday, September 15, 2020 Presentation Time: 10:40 a.m. ET

Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Monday, September 21, 2020 Fireside Chat Time: 2:30 p.m. ET

To access a live webcast and subsequent archived recording of each presentation, please visit "Events" in the "Investors" section of the Kala website at http://kalarx.com.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY(r) mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS(r) (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date set for October 30, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005028/en/

CONTACT: Hannah Deresiewicz hannah.deresiewicz@sternir.com 212-362-1200